BERGEN, Norway, May 18, 2018 /PRNewswire/ —
BerGenBio ASA (OSE: BGBIO) announces that the company and its collaborators will present interim clinical data from its Phase II clinical development programme with bemcentinib, a selective, oral AXL inhibitor, in acute myeloid leukaemia…
GOT NEWS? click here
possible to reach millions worldwide
Google News, Bing News, Yahoo News, 200+ publications
Google News, Bing News, Yahoo News, 200+ publications